Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,100
- 试验地点
- 1
- 主要终点
- Quality of life
研究概览
简要总结
Evaluate the long term efficacy and side effects of oxybutynin in the treatment of hyperhidrosis.
详细描述
This retrospective study aims to evaluate the medical charts of patients who were treated with oxybutynin for at least six months for primary hyperhidrosis. The investigators variables of interest are: (1) quality of life before pharmacological therapy and after six weeks, (2)self-perception of improvement in hyperhidrosis after six weeks of treatment and on last visit (whenever this occur, as long as this happens after six months), (3) side effects related to drug use.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 5 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary hyperhidrosis
- •At least 180 days of treatment with oxybutynin
排除标准
- •Incomplete medical chart
- •Patients with glaucoma
研究组 & 干预措施
Axillary hyperhidrosis
Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
干预措施: Oxybutynin (Drug)
Palmar hyperhidrosis
Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
干预措施: Oxybutynin (Drug)
Plantar hyperhidrosis
Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
干预措施: Oxybutynin (Drug)
Cranio-facial hyperhidrosis
Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
干预措施: Oxybutynin (Drug)
Other sites hyperhidrosis
Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
干预措施: Oxybutynin (Drug)
结局指标
主要结局
Quality of life
时间窗: Forty-two days after treatment
Evaluate the Quality of life (using a standardized questionnaire for hyperhidrotic patients) after 42 days of treatment
次要结局
- Perception of improvement in excessive sweating(1 day (On the last medical visit))
研究者
Nelson Wolosker
PhD
Hospital Israelita Albert Einstein